Pepmixes to generate multiviral CTLs with broad specificity
AssigneeBaylor College of Medicine
InventorsAnn Marie Leen, Juan Fernando Vera Valdes, Cliona M. Rooney, Ulrike Gerdemann
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.
Claims21
A method of providing a cell therapy to an individual in need thereof, comprising administering a composition to the individual, wherein the composition comprises an ex vivo expanded polyclonal population of cytotoxic human T lymphocytes (CTLs) that target two or more viral antigens from two or more different viruses, wherein the CTLs are polyclonal CD4+ and CD8+ CTLs;
- wherein one or more antigens is from a first virus, and one or more antigens is from a second virus;
- and wherein
- (a) the first virus is BK virus, and the one or more antigens are selected from LT and VP-1;
- and
- (b) the second virus is HHV6 virus, and the one or more antigens are selected from U14, U11, U71, U54, and U90.
A method of providing a cell therapy to an individual in need thereof, comprising administering the composition to the individual, wherein the composition comprises an ex vivo expanded population of cytotoxic human T cells (CTLs) that target two or more viral antigens from two or more different viruses, wherein the CTLs are polyclonal CD4+ and CD8+ CTLs reactive to one or more libraries of peptides, said one or more libraries of peptides each comprising peptides that overlap in sequence or span part or all of said two or more viral antigens, wherein each peptide is at least seven amino acids in length,
- wherein one or more antigens is from a first virus, and one or more antigens is from a second virus;
- and wherein
- (a) the first virus is BK virus, and the one or more antigens are selected from LT and VP-1;
- and
- (b) the second virus is HHV6 virus, and the one or more antigens are selected from U14, U11, U71, U54, and U90.
Dependencies are inferred from the claim text.